Traws Pharma Grants Stock Options and RSUs to Executive Team

Reuters12-17

<a href="https://laohu8.com/S/TRAW">Traws Pharma</a> Grants Stock Options and RSUs to Executive Team

Traws Pharma Inc. has announced new equity compensation awards for its executive officers. On December 12, 2025, the company's Compensation Committee approved the grant of stock options and restricted stock units (RSUs) under its Amended and Restated 2021 Incentive Compensation Plan. Chief Executive Officer Iain Dukes received 147,771 options and 36,943 RSUs, Chief Financial Officer Charles Parker received 61,571 options and 15,393 RSUs, and Chief Science Officer, Virology, C. David Pauza received 73,886 options and 18,471 RSUs. Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk were each awarded 65,676 options and 16,419 RSUs. The options have an exercise price of $2.33 per share, a ten-year term, and will vest in full on the first anniversary of the grant date, contingent on continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-121635), on December 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592958804?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 06:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592958804","market":"us","top_or_hot":-1,"title":"Traws Pharma Grants Stock Options and RSUs to Executive Team","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> Grants Stock Options and RSUs to Executive Team\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Traws Pharma Inc. has announced new equity compensation awards for its executive officers. On December 12, 2025, the company's Compensation Committee approved the grant of stock options and restricted stock units (RSUs) under its Amended and Restated 2021 Incentive Compensation Plan. Chief Executive Officer Iain Dukes received 147,771 options and 36,943 RSUs, Chief Financial Officer Charles Parker received 61,571 options and 15,393 RSUs, and Chief Science Officer, Virology, C. David Pauza received 73,886 options and 18,471 RSUs. Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk were each awarded 65,676 options and 16,419 RSUs. The options have an exercise price of $2.33 per share, a ten-year term, and will vest in full on the first anniversary of the grant date, contingent on continued service.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-121635), on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Traws Pharma Grants Stock Options and RSUs to Executive Team</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTraws Pharma Grants Stock Options and RSUs to Executive Team\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 06:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> Grants Stock Options and RSUs to Executive Team\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Traws Pharma Inc. has announced new equity compensation awards for its executive officers. On December 12, 2025, the company's Compensation Committee approved the grant of stock options and restricted stock units (RSUs) under its Amended and Restated 2021 Incentive Compensation Plan. Chief Executive Officer Iain Dukes received 147,771 options and 36,943 RSUs, Chief Financial Officer Charles Parker received 61,571 options and 15,393 RSUs, and Chief Science Officer, Virology, C. David Pauza received 73,886 options and 18,471 RSUs. Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk were each awarded 65,676 options and 16,419 RSUs. The options have an exercise price of $2.33 per share, a ten-year term, and will vest in full on the first anniversary of the grant date, contingent on continued service.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-121635), on December 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRAW","symbol_name":"TRAWS PHARMA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1wrvY7:1","article_id":"2592958804","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592958804","pubTimestamp":1765922477,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Traws Pharma Inc. has announced new equity compensation awards for its executive officers. On December 12, 2025, the company's Compensation Committee approved the grant of stock options and restricted stock units  under its Amended and Restated 2021 Incentive Compensation Plan. Chief Executive Officer Iain Dukes received 147,771 options and 36,943 RSUs, Chief Financial Officer Charles Parker received 61,571 options and 15,393 RSUs, and Chief Science Officer, Virology, C. David Pauza received 73,886 options and 18,471 RSUs. Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk were each awarded 65,676 options and 16,419 RSUs. The options have an exercise price of $2.33 per share, a ten-year term, and will vest in full on the first anniversary of the grant date, contingent on continued service.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRAW":"TRAWS PHARMA","BK4007":"制药"},"translate_title":"Traws Pharma向高管团队授予股票期权和受限制股份单位","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRAW":0.9},"content_text":"Traws Pharma Grants Stock Options and RSUs to Executive Team\n    \n\n        Traws Pharma Inc. has announced new equity compensation awards for its executive officers. On December 12, 2025, the company's Compensation Committee approved the grant of stock options and restricted stock units (RSUs) under its Amended and Restated 2021 Incentive Compensation Plan. Chief Executive Officer Iain Dukes received 147,771 options and 36,943 RSUs, Chief Financial Officer Charles Parker received 61,571 options and 15,393 RSUs, and Chief Science Officer, Virology, C. David Pauza received 73,886 options and 18,471 RSUs. Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk were each awarded 65,676 options and 16,419 RSUs. The options have an exercise price of $2.33 per share, a ten-year term, and will vest in full on the first anniversary of the grant date, contingent on continued service.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-121635), on December 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592958804","isCrawlerRequest":true}